Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01134146 | Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00856830 | Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT01051934 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 49 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00280150 | Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 46 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | completed | Phase 1 | 87 | Genentech, Inc.INDUSTRY | 2 | Jun 7, 2017 | clinicaltrials |
| NCT00046111 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | completed | Phase 1 | 1 | GlaxoSmithKlineINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT00310154 | Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 1 | 45 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02771470 | Intestinal Microflora in Lung Cancer After Chemotherapy | completed | Phase 1 | 41 | Shandong UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00408499 | Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 64 | University of California, DavisOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT00731952 | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | completed | Phase 1 | 21 | University of VirginiaOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00004095 | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 38 | Northwestern UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT01069757 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 16 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01251796 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 9 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT01005797 | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | completed | Phase 1 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00444015 | Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01647711 | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | completed | Phase 1 | 35 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
| NCT00401778 | Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 33 | Emory UniversityOTHER | 1 | Dec 21, 2016 | clinicaltrials |
| NCT00073723 | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 75 | Celgene CorporationINDUSTRY | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00503568 | Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy | completed | Phase 1 | 19 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00032032 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 69 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00876460 | BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00776698 | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00975182 | A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01839955 | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 | 12 | Neelesh Sharma MD PhDOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01605916 | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | completed | Phase 1 | 6 | MorphotekINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Nasser Hanna, M.D.OTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT00850785 | Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer(DRibble) | completed | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02033551 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 | 47 | AbbVieINDUSTRY | 3 | Sep 27, 2016 | clinicaltrials |
| NCT01723800 | PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT01935453 | A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | completed | Phase 1 | 18 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Sep 1, 2016 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02523404 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00496275 | Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC | completed | Phase 1 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 26, 2016 | clinicaltrials |
| NCT00506051 | ZD6474(Vandetanib) + Alimta Combo Study | completed | Phase 1 | 21 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 25, 2016 | clinicaltrials |
| NCT00994123 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 162 | Merrimack PharmaceuticalsINDUSTRY | 6 | Aug 22, 2016 | clinicaltrials |
| NCT00580320 | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2017source: clinicaltrials